This has led to the opening of multiple phase 1/2 studies in patients with R/R AML with KMT2A-rearrangement or NPM1-mutation using the menin-MLL inhibitor KO-539 (NCT04067336) or menin inhibitor SNDX-5613 (NCT04065399, NCT05326516, NCT05406817, NCT05360160, NCT03013998) which are currently enrolling patients or opening soon. The gene discussed is NPM1; the disease is acute myeloid leukemia.